Dahham Alsoud, MD, MSc, PhD
Postdoctoral Scholar, Gastroenterology, Hepatology, and Nutrition
Bio
Dahham Alsoud, MD, MSc, PhD, is a physician-scientist and Postdoctoral Scholar in the Rosen Laboratory at Stanford University School of Medicine. His research seeks to make treatment decisions in inflammatory bowel disease more precise by understanding who benefits from a therapy, why others do not, and which treatment to consider next when a therapy fails or is not tolerated. Building on doctoral work spanning clinical prediction and molecular profiling, he leads cohort analyses and develops analytical strategies within CAPTURE-IBD, integrating multi-omics with longitudinal clinical and patient-reported data. His work connects disease biology with treatment trajectories to inform the selection, sequencing, and optimization of therapies for children and adolescents with IBD.
Dr. Alsoud also serves as Editorial Fellow for Basic and Translational Science at Inflammatory Bowel Diseases. His editorial and peer-review work complements his research interests in rigorous study design, biomarker validation, and the interpretation of translational evidence.
He earned his PhD in Biomedical Sciences at KU Leuven, where he developed a research program through three complementary first-author studies: evaluating and updating clinical decision support tools, investigating the molecular rationale for potential combination therapies, and developing and validating serum proteomic models of biologic response. His broader contributions span therapeutic drug monitoring, biomarker validation, less invasive disease assessment, and comparative effectiveness.
Dr. Alsoud also holds an MSc in Health Care Management and Policy from KU Leuven and an MD from Damascus University. His postdoctoral research has been supported by the Stanford Medicine Children’s Health Center for IBD and Celiac Disease and the Belgian American Educational Foundation.
Honors & Awards
-
Postdoctoral Award, Stanford Medicine Children’s Health Center for IBD and Celiac Disease (2026–2027)
-
Postdoctoral Research Fellowship, Belgian American Educational Foundation (2025)
-
Travel Grant, Research Foundation – Flanders (FWO) (2022)
-
Research Grant, Flanders Crohn’s and Colitis Patients Association (CCV VZW) (2020)
Boards, Advisory Committees, Professional Organizations
-
Editorial Fellow, Basic and Translational Science, Inflammatory Bowel Diseases (2026 - Present)
Professional Education
-
PhD, KU Leuven, Belgium, Biomedical Sciences (2026)
-
MSc, KU Leuven, Belgium, Health Care Management and Policy (2024)
-
MD, Damascus University, Syria, Medicine (2015)
Current Research and Scholarly Interests
My research aims to move inflammatory bowel disease care toward a future in which treatment selection, sequencing, and optimization are guided by an understanding of each patient’s disease biology and clinical trajectory. The central question driving my work is how to translate treatment-response heterogeneity into actionable knowledge: who benefits from a therapy, why others do not, and what should come next.
My doctoral research at KU Leuven established a foundation for this program through three complementary first-author studies. I evaluated and updated clinical decision support tools, investigated the molecular rationale for potential combination therapies using longitudinal transcriptomics, and developed and validated serum proteomic models of biologic response. Together, these studies connected clinical prediction with molecular mechanisms and demonstrated the importance of assessing calibration, clinical utility, and biological context when developing tools for precision medicine.
At Stanford’s Rosen Laboratory, I am extending this foundation to pediatric IBD through CAPTURE-IBD. I lead cohort analyses and develop analytical strategies that integrate multi-omics with longitudinal clinical and patient-reported data. This work investigates the biological drivers of response heterogeneity, determinants of success and failure across treatment sequences, and the relationships between psychosocial distress, symptoms, and disease outcomes. My longer-term goal is to help develop and prospectively test treatment strategies that account for both disease biology and how a patient’s course evolves over time.
My broader contributions provide complementary foundations for this vision: defining exposure-response relationships, investigating infliximab clearance, developing guidance for therapeutic drug monitoring, evaluating less invasive measures of inflammation, and testing prognostic biomarkers across clinical contexts. Real-world effectiveness studies, evidence synthesis, and work on therapeutic resistance and translational research standards further connect molecular discovery with the decisions clinicians face. Building on these contributions, I aim to bring treatment selection, monitoring, and timely adaptation into a more integrated approach to achieving durable remission.
Projects
-
CAPTURE-IBD: Understanding Treatment Heterogeneity in Pediatric IBD, Stanford University School of Medicine
Within CAPTURE-IBD, I lead analyses that aim to advance precision medicine for children and adolescents with inflammatory bowel disease. Working with Michael J. Rosen and the study investigators, I integrate molecular profiling with longitudinal clinical and patient-reported data across three complementary projects.
1. Molecular and immune heterogeneity: integrating serum proteomics and immunophenotyping to unravel reasons for differences in response to biologics and advanced small-molecule therapies.
2. Treatment sequencing: characterizing cycling across advanced therapies and identifying determinants of treatment failure and persistence.
3. Psychosocial distress and patient-reported outcomes: examining their relationships with objective inflammation and subsequent disease outcomes.
My responsibilities include leading cohort analyses, developing analysis plans, coordinating collaborators, presenting findings to study principal investigators, and leading manuscript development. These ongoing studies aim to generate clinically relevant hypotheses and evidence for more individualized treatment decisions.Location
Stanford, California, United States
-
From Clinical Prediction to Molecular Treatment Selection in IBD, KU Leuven
My PhD at KU Leuven brought together three first-author studies addressing unmet needs in precision medicine from complementary angles.
Clinical decision support: I evaluated and updated tools for selecting vedolizumab and ustekinumab, examining calibration and clinical usefulness alongside discrimination. This work, published in Clinical Gastroenterology and Hepatology, showed why prediction tools require careful evaluation and updating before they can inform treatment decisions.
Whole-blood transcriptomics: I investigated molecular compatibility and complementarity across advanced therapies in ulcerative colitis, using longitudinal transcriptional profiles to prioritize potential combination strategies for further testing. These analyses generate hypotheses about combinations; they do not establish clinical efficacy or safety. “Whole-blood Transcriptomics Reveal Molecular Compatibility and Complementarity Across Advanced Therapies in Ulcerative Colitis” is accepted for publication in Journal of Crohn’s and Colitis (doi:10.1093/ecco-jcc/jjag194).
Serum proteomics: I developed and validated baseline serum proteomic models of biologic response in Crohn’s disease, examining the value of molecular information alongside clinical predictors. “Baseline Serum Proteomics Predicts Biologic Therapy Response in Crohn’s Disease” is under peer review.
Together, these studies connect evaluation of existing clinical tools, investigation of potential combination therapies, and molecular prediction of treatment outcomes. The doctoral program was supervised by Séverine Vermeire and Bram Verstockt.
Published clinical decision-support study
Alsoud D, Sabino J, Ferrante M, et al. Calibration, Clinical Utility, and Specificity of Clinical Decision Support Tools in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2025. doi: 10.1016/j.cgh.2024.09.020Location
Leuven, Belgium
-
Infliximab Clearance and Therapeutic Drug Monitoring, Stanford University; KU Leuven
My pediatric infliximab research examines pharmacokinetic risk across moderately and severely active ulcerative colitis, extending the question of rapid clearance beyond acute severe disease. The study highlights shared pharmacokinetic risk across severity settings and provides a basis for further investigation of individualized dosing.
I was also first author of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology position statement on infliximab monitoring, synthesizing evidence and practical considerations for interpreting drug concentrations. Related work examines aging and infliximab exposure, monitoring of vedolizumab and ustekinumab, and the interpretation of immunogenicity in loss of response to anti-TNF therapy.
Together, these contributions address how pharmacokinetic information can be interpreted alongside patient characteristics, inflammation, and mechanisms of treatment failure.
Accepted publication
Alsoud D, et al. High Infliximab Clearance Spans Moderately and Severely Active Pediatric Ulcerative Colitis, Signaling Shared Pharmacokinetic Risk. Inflammatory Bowel Diseases. Accepted for publication.
Related publications
Alsoud D, Moes DJAR, Wang Z, et al. Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Ther Drug Monit. 2024. doi: 10.1097/FTD.0000000000001204
Alsoud D, Verstockt B, Vermeire S. Letter: immunogenicity is not the root cause for loss of response to anti-TNF agents in patients with IBD in TDM era. Aliment Pharmacol Ther. 2022. doi: 10.1111/apt.16797
Kantasiripitak W, Verstockt B, Alsoud D, et al. The effect of aging on infliximab exposure and response in patients with inflammatory bowel diseases. Br J Clin Pharmacol. 2021. doi: 10.1111/bcp.14785
Alsoud D, Vermeire S, Verstockt B. Monitoring vedolizumab and ustekinumab drug levels in patients with inflammatory bowel disease: hype or hope? Curr Opin Pharmacol. 2020. doi: 10.1016/j.coph.2020.09.002Location
Stanford, California, United States
-
Drug Exposure and Molecular Effects as Determinants of Treatment Response, KU Leuven
Why do adequate drug concentrations not always translate into disease control? This research examines the relationship between systemic exposure, tissue drug concentrations, downstream molecular effects, and therapeutic outcomes in IBD.
In my first-author prospective ulcerative colitis study, ustekinumab exposure correlated with endoscopic and histological outcomes. In collaborative tofacitinib studies, I investigated tissue drug concentrations and STAT3 modulation, connecting pharmacology with biological effects in the intestinal mucosa. Related work assessed whether pharmacogenetic determinants of anti-TNF exposure also apply to vedolizumab and ustekinumab.
Together, these studies help distinguish insufficient exposure from other explanations for treatment failure and define questions for future individualized dosing studies. Observed exposure-response associations do not, by themselves, establish that dose escalation improves outcomes.
Related publications
Verstockt B, Alsoud D, van Oostrom J, et al. Drug tissue concentration and STAT3 modulation as determinants of tofacitinib response in ulcerative colitis. J Crohns Colitis. 2025. doi: 10.1093/ecco-jcc/jjaf063
Alsoud D, Verstockt B, Vermeire S. Ustekinumab and Vedolizumab Exposure Is Unaffected by Pharmacogenetic Determinants of Anti-TNFs Pharmacokinetics. Inflamm Bowel Dis. 2024. doi: 10.1093/ibd/izae035
Alsoud D, De Hertogh G, Compernolle G, et al. Real-world Endoscopic and Histological Outcomes Are Correlated with Ustekinumab Exposure in Patients with Ulcerative Colitis. J Crohns Colitis. 2022. doi: 10.1093/ecco-jcc/jjac067
Verstockt B, Volk V, Jaeckel C, et al. Longitudinal monitoring of STAT3 phosphorylation and histologic outcome of tofacitinib therapy in patients with ulcerative colitis. Aliment Pharmacol Ther. 2022. doi: 10.1111/apt.16955Location
Leuven, Belgium
-
Less Invasive Monitoring of Inflammation and Therapeutic Response, KU Leuven; Stanford University
This research investigates whether blood-based biomarkers can track intestinal inflammation and treatment response while reducing the burden of repeated disease assessment.
In first-author work involving 127 patients with ulcerative colitis and 303 paired samples, I evaluated the Endoscopic Healing Index, a serum test originally developed for Crohn’s disease. The index tracked changes in mucosal inflammation and distinguished endoscopic improvement from persistent activity. Related work examined its use in Crohn’s disease and evaluated serum cytokines and acute-phase proteins during ustekinumab therapy.
My ongoing work on intestinal ultrasound in young children extends this interest to imaging, examining how bowel-wall measurements and other ultrasound findings relate to biochemical disease activity. The goal is to establish the performance and limitations of less invasive measures in their intended clinical settings.
Related publications
Alsoud D, Ho J, Sabino J, et al. Utility of the Serum-Based Endoscopic Healing Index in Monitoring Therapeutic Response in Ulcerative Colitis. Am J Gastroenterol. 2024. doi: 10.14309/ajg.0000000000002518
Van den Berghe N, Alsoud D, Verstockt B, et al. Evaluation of serum cytokines and acute phase proteins as possible pharmacodynamic biomarkers to monitor endoscopic remission during ustekinumab therapy in patients with Crohn's disease. Ther Adv Gastroenterol. 2023. doi: 10.1177/17562848231189110
Alsoud D, Ho J, Verstockt B. The Serum-Based Endoscopic Healing Index Can Monitor Therapeutic Response in Crohn's Disease. J Crohns Colitis. 2023. doi: 10.1093/ecco-jcc/jjad077Location
Leuven, Belgium; Stanford, California, United States
-
Prognostic Biomarker Validation and Reliable Clinical Prediction, KU Leuven
A biomarker is useful only if it performs reliably in the patients and treatment context in which it will be used. As first author of a multinational evaluation of PredictSURE IBD, I investigated disease-course stratification and the effects of corticosteroid exposure on a blood-based prognostic classifier.
We observed separation in treatment-escalation outcomes among corticosteroid-naive patients with ulcerative colitis, but no significant separation in Crohn’s disease. Corticosteroid exposure also altered classification, underscoring the importance of treatment context when interpreting molecular biomarkers.
My methodological work with Ben Van Calster argues for assessment of calibration and clinical utility alongside discrimination. This complements my doctoral evaluation of clinical decision support tools and informs my current approach to biomarker validation and longitudinal outcome modeling.
Related publications
Alsoud D, Noor NM, Chen LA, et al. Assessment of PredictSURE IBD Assay in a Multinational Cohort of Patients With Inflammatory Bowel Disease. United European Gastroenterol J. 2025. doi: 10.1002/ueg2.70050
Alsoud D, Van Calster B. Beyond Discrimination: A Call for Comprehensive Assessment of Clinical Prediction Models in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2024. doi: 10.1093/ibd/izae048Location
Leuven, Belgium
-
Real-World Effectiveness and Comparative Treatment Strategies in IBD, KU Leuven and collaborating centers
This research examines how advanced therapies perform in routine practice, including patients with multiple prior treatment failures who may be poorly represented in pivotal trials.
My first-author Belgian multicenter study evaluated risankizumab effectiveness and safety in multirefractory Crohn’s disease. I also contributed to observational comparisons of adalimumab with vedolizumab and ustekinumab as first-line biologic treatments.
A related methodological commentary examines how study design and patient selection affect the fairness of comparisons used to position therapies. Across this work, I aim to interpret effectiveness estimates in light of prior exposure, baseline risk, confounding, and the clinical decision being addressed.
Related publications
Alsoud D, Sabino J, Franchimont D, et al. Real-world Effectiveness and Safety of Risankizumab in Patients with Moderate to Severe Multirefractory Crohn's Disease: A Belgian Multicentric Cohort Study. Inflamm Bowel Dis. 2024. doi: 10.1093/ibd/izad315
Alsoud D, Verstockt B, Vermeire S. Comparative Effectiveness Research to Position Therapies in Ulcerative Colitis: How Fair Are the Comparisons? Clin Gastroenterol Hepatol. 2023. doi: 10.1016/j.cgh.2022.06.017
Moens A, Alsoud D, Verstockt B, et al. Adalimumab versus ustekinumab as first-line biological in moderate-to-severe Crohn's disease: real-life cohort from a tertiary referral center. Eur J Gastroenterol Hepatol. 2022. doi: 10.1097/MEG.0000000000002411
Moens A, Verstockt B, Alsoud D, et al. Translating Results from VARSITY to Real World: Adalimumab vs Vedolizumab as First-line Biological in Moderate to Severe IBD. Inflamm Bowel Dis. 2022. doi: 10.1093/ibd/izab257Location
Leuven, Belgium
-
Evidence Synthesis and Critical Appraisal of Emerging IBD Therapies, KU Leuven and international collaborators
I contribute to systematic reviews and meta-analyses that evaluate the expanding range of advanced therapies for Crohn’s disease and ulcerative colitis. These projects include network comparisons of IL-12/23 and selective IL-23 inhibitors during induction and maintenance, and comparisons of IL-12/23 inhibition with anti-TNF therapy in biologic-naive Crohn’s disease.
The work organizes evidence across trials and cohorts to clarify comparative efficacy while accounting for differences in populations, endpoints, and study design. Treatment rankings from indirect comparisons require cautious interpretation and do not replace head-to-head evidence.
My coauthored commentary on mirikizumab in ulcerative colitis extends this interest to the clinical meaning of incremental advances within an expanding therapeutic class.
Related publications
Al Hayek M, Sawaf B, Beshr MS, et al. Comparative Efficacy of IL-12/23 and IL-23 Inhibitors for Induction and Maintenance Therapy in Moderate-to-Severe Crohn's Disease: A Systematic Review and Network Meta-Analysis. Inflamm Intest Dis. 2025. doi: 10.1159/000547707
Sawaf B, Hayek MA, Kassem A, et al. Interleukin 12/23 and interleukin 23 inhibitors for moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Ann Gastroenterol. 2025. doi: 10.20524/aog.2025.1009
Al Hayek M, Sawaf B, Abbarh S, et al. Anti-IL 12/23 versus Anti-Tumor Necrosis Factor-α in Patients with Biologically Naïve Crohn's Disease: A Systematic Review and Meta-analysis. Inflamm Intest Dis. 2025. doi: 10.1159/000546858
Sawaf B, Abbarh S, Alsoud D. Mirikizumab for Ulcerative Colitis: A Game-Changer or Just Another Incremental Advance? Dig Dis Sci. 2025. doi: 10.1007/s10620-025-09047-2Location
Leuven, Belgium
-
Therapeutic Resistance, Multi-Omics, and Standards for Translational Research, KU Leuven and international collaborators
Why does durable remission remain elusive despite an expanding range of IBD therapies? My first-author review on the therapeutic ceiling in ulcerative colitis examines this problem in the context of drug development and frames the questions pursued in my later clinical and molecular research.
A further first-author review addresses the challenges and promises of biomarker discovery for personalized treatment selection. I also contributed to work on integrating multi-omics in IBD and to expert recommendations for standardizing transcriptomic analyses in clinical trials.
These contributions connect therapeutic resistance with the methods needed to generate reproducible molecular evidence: thoughtful study design, appropriate validation, integration of complementary data types, and transparent interpretation.
Related publications
Linggi B, Azucena S, Steere B, et al. Expert recommendations to standardize transcriptomic analysis in inflammatory bowel disease clinical trials. J Crohns Colitis. 2025. doi: 10.1093/ecco-jcc/jjaf068
Sudhakar P, Alsoud D, Wellens J, et al. Tailoring Multi-omics to Inflammatory Bowel Diseases: All for One and One for All. J Crohns Colitis. 2022. doi: 10.1093/ecco-jcc/jjac027
Alsoud D, Vermeire S, Verstockt B. Biomarker discovery for personalized therapy selection in inflammatory bowel diseases: Challenges and promises. Curr Res Pharmacol Drug Discov. 2022. doi: 10.1016/j.crphar.2022.100089
Alsoud D, Verstockt B, Fiocchi C, et al. Breaking the therapeutic ceiling in drug development in ulcerative colitis. Lancet Gastroenterol Hepatol. 2021. doi: 10.1016/S2468-1253(21)00065-0Location
Leuven, Belgium
All Publications
-
Interleukin 12/23 and interleukin 23 inhibitors for moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis.
Annals of gastroenterology
2025; 38 (6): 648-660
Abstract
Ulcerative colitis (UC) is a chronic inflammatory disease affecting ~1.5 million individuals, causing significant impairment in quality of life, psychological well-being, and healthcare burden. Using indirect meta-analysis, this study compared the efficacy and safety of anti-interleukin (IL)-12/23 and IL-23 agents vs. placebo and each other, during induction and maintenance in moderate-to-severe UC.A systematic search of PubMed, Cochrane, Scopus, Web of Science, and ClinicalTrials. gov was conducted on October 1, 2024. The randomized controlled trials (RCTs) included evaluated ustekinumab, mirikizumab, risankizumab, and guselkumab. The primary outcomes were clinical remission and endoscopic improvement at both induction and maintenance endpoints. Odds ratios (ORs) with 95% confidence intervals (CIs) and surface under the cumulative ranking (SUCRA) values were used to rank treatment efficacy.Six RCTs (n=3808) were analyzed for induction and 5 RCTs (n=1697) for maintenance. During induction, risankizumab demonstrated the highest clinical remission rates (OR 3.89, 95%CI 2.24-6.75; SUCRA 80.7%) and endoscopic improvement rates (OR 4.21, 95%CI 2.12-8.35; SUCRA 87.6%) compared to placebo. In maintenance, guselkumab showed the highest clinical remission (OR 4.28, 95%CI 1.58-11.59; SUCRA 81.6%) and endoscopic improvement (OR 4.21, 95%CI 2.12-8.35; SUCRA 93.1%), and was superior to risankizumab (OR 2.05, 95%CI 1.09-3.84) for endoscopic outcomes.Risankizumab was most effective in induction, while guselkumab was more effective in maintenance. Head-to-head trials are warranted.
View details for DOI 10.20524/aog.2025.1009
View details for PubMedID 41586395
View details for PubMedCentralID PMC12829535
-
Assessment of PredictSURE IBD Assay in a Multinational Cohort of Patients With Inflammatory Bowel Disease.
United European gastroenterology journal
2025; 13 (8): 1525-1540
Abstract
PredictSURE IBD is a prognostic blood test that classifies newly diagnosed, treatment-naïve Inflammatory Bowel Disease (IBD) patients into 'IBDhi' (high-risk) or 'IBDlo' (low-risk) groups (risk of future aggressive disease). We evaluated this assay in a multinational cohort and explored the effect of concomitant corticosteroids on its discrimination.One hundred thirty-six (71 Ulcerative colitis [UC], 65 Crohn's Disease [CD]) and 41 (15 UC, 26 CD) patients with active IBD were 'unexposed' and 'exposed', respectively, to corticosteroids at baseline blood sampling. The number of treatment escalations, time to first escalation, and need for repeated escalations were compared between the biomarker subgroups. Another 20 patients (13 UC, 7 CD) were longitudinally sampled over 6 weeks after commencing corticosteroids.In corticosteroids-naïve UC and CD patients, all bowel surgeries (n = 6) and multiple therapy escalations (n = 10) occurred in IBDhi patients. IBDhi UC patients required significantly more treatment escalations, had a shorter time to first escalation, and a greater need for multiple escalations than IBDlo patients. No statistically significant differences were observed among CD patients. In corticosteroid-exposed patients, 66.6% of 'misclassifications' were IBDlo patients who required escalations. Among corticosteroid-treated patients with longitudinal sampling, 81.3% of those classified as IBDhi before steroids switched to IBDlo during therapy.No significant differences in treatment escalations were observed between biomarker-defined subgroups in CD. However, IBDhi UC patients required significantly earlier and more frequent therapy escalations, highlighting the need to further investigate PredictSURE IBD in UC. Notably, the discrimination ability of the biomarker was unreliable in patients receiving corticosteroid therapy.
View details for DOI 10.1002/ueg2.70050
View details for PubMedID 40641434
View details for PubMedCentralID PMC12528995
-
Comparative Efficacy of IL-12/23 and IL-23 Inhibitors for Induction and Maintenance Therapy in Moderate-to-Severe Crohn's Disease: A Systematic Review and Network Meta-Analysis.
Inflammatory intestinal diseases
2025; 10 (1): 265-284
Abstract
Interleukin (IL)-12/23 and IL-23 inhibitors have emerged as promising therapeutic options for moderate-to-severe Crohn's disease (CD), but comparative data between agents remain limited. This study aimed to assess and rank the efficacy of IL-12/23 and IL-23 inhibitors across key clinical and endoscopic outcomes using network meta-analysis.We included randomized controlled trials (RCTs) evaluating IL-12/23 (ustekinumab) and IL-23 inhibitors (risankizumab, mirikizumab, guselkumab, briakinumab, and MEDI2070) versus placebo or each other in adult patients with moderate-to-severe CD. Primary outcomes included clinical and endoscopic remission (assessed at the end of the induction and maintenance phases) and corticosteroid-free clinical remission (assessed at the end of the maintenance phase). Risk ratios (RRs) were estimated using a random-effects model. All analyses were conducted in R using the netmeta package. Surface under the cumulative ranking curve (SUCRA) analysis was used to rank treatments across these endpoints.Fourteen RCTs involving 4,464 patients during the induction phase and 2,601 patients during the maintenance phase were included. Guselkumab achieved the highest clinical remission rate compared to placebo at the end of both the induction phase (RR = 2.62; 95% confidence interval [CI], 2.03-3.39; SUCRA: 91%) and the maintenance phase (RR = 2.37; 95% CI, 1.64-3.42; SUCRA: 85%). In addition, guselkumab was superior to mirikizumab in terms of clinical remission at the end of the induction phase (RR = 1.66; 95% CI, 1.16-2.37). Guselkumab was also the most effective agent for achieving corticosteroid-free clinical remission compared to placebo (RR = 3.06; 95% CI, 1.52-6.16; SUCRA: 78%) at the end of the maintenance phase. Mirikizumab achieved the highest endoscopic remission rate compared to placebo at the end of both the induction phase (RR = 3.52; 95% CI, 1.50-8.27; SUCRA: 78%) and the maintenance phase (RR = 5.84; 95% CI, 2.76-12.37; SUCRA: 88%). Furthermore, mirikizumab, guselkumab, and risankizumab were superior to ustekinumab in terms of endoscopic remission at the end of the maintenance phase.These findings suggest that guselkumab may be a potential first-line therapy for patients presenting with predominant clinical symptoms, offering the additional benefit of reducing corticosteroid use and its associated long-term risks. Conversely, mirikizumab may be the preferred option for patients with persistent mucosal inflammation, owing to its superior efficacy in achieving endoscopic remission.
View details for DOI 10.1159/000547707
View details for PubMedID 41064350
View details for PubMedCentralID PMC12503645
-
Anti-IL 12/23 versus Anti-Tumor Necrosis Factor-α in Patients with Biologically Naïve Crohn's Disease: A Systematic Review and Meta-analysis.
Inflammatory intestinal diseases
2025; 10 (1): 169-179
Abstract
Crohn's disease (CD) is a chronic inflammatory condition of the digestive tract, characterized by a noncontinuous pattern of transmural inflammation, leading to a significant decline in quality of life and productivity. For biologic-naïve patients, anti-tumor necrosis factor (TNF)-α and anti-interleukin (IL)-12/23 therapies are commonly recommended. This study compares anti-IL-12/23 and anti-TNF-α for clinical remission, corticosteroid-free remission, endoscopic remission, and endoscopic response in biologic-naïve patients.We searched PubMed, Google Scholar, VHL, Cochrane Library, Scopus, Web of Science, and ClinicalTrials.gov for randomized clinical trials and cohort studies. Data were analyzed using odds ratios (ORs) with 95% confidence intervals (CIs). A random-effects model was applied for meta-analysis.Only 6 out of 5,401 articles were included, involving a total of 1,103 patients. Of these, 636 (57.6%) received anti-TNF-α therapy (infliximab or adalimumab), while 467 (42.4%) received anti-IL-12/23 (ustekinumab) therapy. Within 52 weeks, there were no statistically significant differences found between Ustekinumab and anti-TNF-α in terms of clinical remission (OR: 0.92, 95% CI: 0.55-1.54, p = 0.75), endoscopic remission (OR = 0.583, 95% CI: 0.289-1.176; p = 0.13), corticosteroid-free remission (OR: 1.19, 95% CI: 0.87-1.64, p = 0.28), or endoscopic response (OR = 0.48, 95% CI: 0.147-1.578; p = 0.23).This meta-analysis found no significant differences in clinical remission, corticosteroid-free remission, endoscopic remission, or endoscopic response within 52 weeks between ustekinumab and anti-TNF-α agents in biologic-naïve CD patients. However, due to study limitations, further high-quality, head-to-head trials are needed to refine treatment selection and optimize outcomes.
View details for DOI 10.1159/000546858
View details for PubMedID 40635760
View details for PubMedCentralID PMC12240579
-
Calibration, Clinical Utility, and Specificity of Clinical Decision Support Tools in Inflammatory Bowel Disease.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
2025; 23 (7): 1216-1227.e14
Abstract
Clinical decision support tools (CDSTs) have been developed to predict response to vedolizumab (VDZ) and ustekinumab (UST) in Crohn's disease (CD) and ulcerative colitis (UC). In addition to assessing their discrimination performance, our study aimed to evaluate their calibration, clinical utility, and specificity.We included 280 patients with CD and 218 patients with UC initiating VDZ, and 194 patients with CD initiating UST. We assessed discrimination by comparing rates of effectiveness outcomes between response probability groups forecasted by CDSTs. Calibration curves and decision curve analysis evaluated the calibration and clinical utility of VDZ-CDSTs. Additionally, we examined the agreement between UST-CDST and VDZ-CDST in assigning response probability groups among patients with CD starting UST.In the overall cohort, CDSTs allocated 7.2%, 50.0%, and 42.8% of the patients to the low-, intermediate-, and high-response probability groups, respectively. VDZ-CDSTs groups demonstrated significant differences in the rates of clinical and endoscopic response and remission, whereas UST-CDST groups showed significant discrimination only for clinical remission. Although VDZ-CDSTs overestimated clinical remission rates, they more accurately predicted rates of VDZ persistence without need for surgery or dose escalation. Compared with empirically treating all patients with VDZ, VDZ-CDSTs yielded higher net benefits in selecting patients who would continue VDZ without need for surgery or dose escalation. Finally, the agreement between UST-CDST and VDZ-CDST in predicting response was 73.7%.VDZ-CDSTs significantly discriminated response to VDZ and were more beneficial in identifying patients who would continue therapy without requiring surgery or dose escalation, compared with treating all patients empirically.
View details for DOI 10.1016/j.cgh.2024.09.020
View details for PubMedID 39461468
-
Mirikizumab for Ulcerative Colitis: A Game-Changer or Just Another Incremental Advance?
Digestive diseases and sciences
2025; 70 (6): 1946-1947
View details for DOI 10.1007/s10620-025-09047-2
View details for PubMedID 40237908
-
Drug tissue concentration and STAT3 modulation as determinants of tofacitinib response in ulcerative colitis.
Journal of Crohn's & colitis
2025; 19 (5)
Abstract
Inflammatory bowel disease management has advanced with therapies like Janus kinase inhibitors (JAKi). Despite their promise, JAKi pharmacokinetic-pharmacodynamic (PK-PD) profiles and tissue-level effects remain underexplored. This study investigates tissue and serum tofacitinib levels, their correlation with therapeutic efficacy, and molecular mechanisms underlying treatment response.Thirty refractory ulcerative colitis (UC) patients receiving tofacitinib were prospectively studied. Tissue biopsies and serum samples were collected pre- and post-induction for PK analysis using liquid chromatography mass spectrometry. RNA sequencing and cytokine profiling were performed on tissue samples to explore molecular responses. Endoscopic improvement was defined as a Mayo endoscopic subscore of 0-1 by week 16.Tofacitinib tissue concentrations were 25-fold higher than serum levels and significantly correlated (ρ=0.92, P < .001). Responders showed significantly higher tissue drug exposure (1047.5 ng/g vs 467.1 ng/g, P = .02) at the time of endoscopic assessment. Tofacitinib treatment reduced phosphorylated STAT3 (pSTAT3) levels, particularly in responders (P = .02). RNA sequencing revealed gene modules linked to tissue drug and pSTAT3 concentrations. Gene set enrichment analysis showed that these were more frequent in non-responders and associated with JAK-STAT pathways.This study underscores the importance of tissue tofacitinib levels in UC treatment efficacy, with pSTAT3 reduction serving as a potential marker of drug efficacy. RNA sequencing identified molecular pathways for potential biomarkers and novel therapeutic targets in tofacitinib non-responders.
View details for DOI 10.1093/ecco-jcc/jjaf063
View details for PubMedID 40243193
-
Expert recommendations to standardize transcriptomic analysis in inflammatory bowel disease clinical trials.
Journal of Crohn's & colitis
2025; 19 (5)
Abstract
Substantial methodological and reporting heterogeneity confounds the interpretation and generalizability of transcriptomic data for inflammatory bowel disease (IBD) studies. We aimed to develop recommendations to standardize transcriptomic research in clinical trials.A 2-part study was undertaken. A systematic review identified reports of transcriptomic analyses utilizing samples from IBD clinical trials. Studies that used global RNA assay platforms were included. Data regarding study design, methodological approaches, and reporting of transcriptomic research were extracted. The systematic review results informed a modified Research and Development/University of California Los Angeles appropriateness methodology process and the development of survey statements focused on topics with substantial methodological heterogeneity. A panel of 16 IBD translational researchers and gastroenterologists rated the appropriateness of survey statements in 2 rounds.The systematic review identified 37 reports that included transcriptomic analyses of samples from IBD patients. The appropriateness of 416 statements was rated by 15 panellists in the first survey. The final survey included 305 statements, of which 14 panellists rated 75% appropriate, 1% inappropriate, and 24% uncertain. The panel determined that transcriptomic analysis for multiple research objectives was appropriate at most phases of clinical development in patients with active disease. Recommendations regarding study sample size; biopsy number, location, preservation, and storage; and data analysis and reporting were also generated.The persistence of existing methodologic heterogeneity may continue to limit the value of transcriptomic research in IBD. This study provides expert recommendations to address and overcome these discrepancies and foster the inclusion of this research in clinical development.
View details for DOI 10.1093/ecco-jcc/jjaf068
View details for PubMedID 40295219
-
Real-world Effectiveness and Safety of Risankizumab in Patients with Moderate to Severe Multirefractory Crohn's Disease: A Belgian Multicentric Cohort Study.
Inflammatory bowel diseases
2024; 30 (12): 2289-2296
Abstract
As real-world data on risankizumab in patients with moderate to severe Crohn's disease (CD) are scarce, we evaluated its effectiveness and safety in multirefractory Belgian patients.Data from consecutive adult CD patients who started risankizumab before April 2023 were retrospectively collected at 6 Belgian centers. Clinical remission and response were defined using the 2-component patient-reported outcome. Endoscopic response was defined as a decrease in baseline Simple Endoscopic Score with ≥50%. Both effectiveness end points were evaluated at week 24 and/or 52, while surgery-free survival and safety were assessed throughout follow-up.A total of 69 patients (56.5% female, median age 37.2 years, 85.5% exposed to ≥4 different advanced therapies and 98.6% to ustekinumab, 14 with an ostomy) were included. At week 24, 61.8% (34 of 55) and 18.2% (10 of 55) of patients without an ostomy achieved steroid-free clinical response and remission, respectively. At week 52, these numbers were 58.2% (32 of 55) and 27.3% (15 of 55), respectively. Endoscopic data were available in 32 patients, of whom 50.0% (16 of 32) reached endoscopic response within the first 52 weeks. Results in patients with an ostomy were similar (steroid-free clinical response and remission, 42.9% and 14.3%, respectively). During a median follow-up of 68.3 weeks, 18.8% (13 of 69) of patients discontinued risankizumab, and 20.3% (14 of 69) of patients underwent CD-related intestinal resections. The estimated surgery-free survival at week 52 was 75.2%. No new safety issues were observed.In this real-world cohort of multirefractory CD patients, risankizumab was effective in inducing both clinical remission and endoscopic response. Risankizumab was well tolerated with no safety issues.
View details for DOI 10.1093/ibd/izad315
View details for PubMedID 38215029
-
Beyond Discrimination: A Call for Comprehensive Assessment of Clinical Prediction Models in Inflammatory Bowel Disease.
Inflammatory bowel diseases
2024; 30 (6): 1050-1051
View details for DOI 10.1093/ibd/izae048
View details for PubMedID 38460148
-
Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology.
Therapeutic drug monitoring
2024; 46 (3): 291-308
Abstract
Infliximab, an anti-tumor necrosis factor monoclonal antibody, has revolutionized the pharmacological management of immune-mediated inflammatory diseases (IMIDs). This position statement critically reviews and examines existing data on therapeutic drug monitoring (TDM) of infliximab in patients with IMIDs. It provides a practical guide on implementing TDM in current clinical practices and outlines priority areas for future research.The endorsing TDM of Biologics and Pharmacometrics Committees of the International Association of TDM and Clinical Toxicology collaborated to create this position statement.Accumulating data support the evidence for TDM of infliximab in the treatment of inflammatory bowel diseases, with limited investigation in other IMIDs. A universal approach to TDM may not fully realize the benefits of improving therapeutic outcomes. Patients at risk for increased infliximab clearance, particularly with a proactive strategy, stand to gain the most from TDM. Personalized exposure targets based on therapeutic goals, patient phenotype, and infliximab administration route are recommended. Rapid assays and home sampling strategies offer flexibility for point-of-care TDM. Ongoing studies on model-informed precision dosing in inflammatory bowel disease will help assess the additional value of precision dosing software tools. Patient education and empowerment, and electronic health record-integrated TDM solutions will facilitate routine TDM implementation. Although optimization of therapeutic effectiveness is a primary focus, the cost-reducing potential of TDM also merits consideration.Successful implementation of TDM for infliximab necessitates interdisciplinary collaboration among clinicians, hospital pharmacists, and (quantitative) clinical pharmacologists to ensure an efficient research trajectory.
View details for DOI 10.1097/FTD.0000000000001204
View details for PubMedID 38648666
-
Ustekinumab and Vedolizumab Exposure Is Unaffected by Pharmacogenetic Determinants of Anti-TNFs Pharmacokinetics.
Inflammatory bowel diseases
2024; 30 (5): 874-875
View details for DOI 10.1093/ibd/izae035
View details for PubMedID 38581670
-
Utility of the Serum-Based Endoscopic Healing Index in Monitoring Therapeutic Response in Ulcerative Colitis.
The American journal of gastroenterology
2024; 119 (3): 477-485
Abstract
Convenient and objective noninvasive tools to monitor therapy response in patients with ulcerative colitis (UC) are needed. This study aimed to evaluate the performance of the Endoscopic Healing Index [EHI], a serum test originally developed to monitor mucosal inflammation in Crohn's disease, in patients with UC.Serum samples paired with endoscopic data from consecutive adult patients with UC initiating advanced therapy for active disease (Mayo Endoscopic Subscore [MES] > 1) were analyzed. EHI values were compared between groups showing endoscopic improvement, remission, and nonresponse, defined, respectively, as MES of ≤1, 0 and >1. We also assessed the association of EHI with longitudinal changes of MES and compared its performance with that of fecal calprotectin (FC) and C-reactive protein.A total of 127 patients provided 303 samples. Median EHI increased significantly with increasing MES score ( P < 0.001). Median EHI was significantly lower in patients with endoscopic remission or improvement compared with patients with no response ( P < 0.001, P < 0.001, respectively). A 10-point decrease in EHI was associated with 89% higher odds of 1-point decrease in MES ( P < 0.001). EHI detected MES 0-1 with an area under the receiver operating curve of 77.8%, which was comparable with that of FC and C-reactive protein (85.0% [ P = 0.076] and 70.6% [ P = 0.055], respectively).EHI values are significantly responsive to changes in mucosal inflammation, also in patients with UC, and can confirm and/or rule out mucosal inflammation with an almost similar accuracy to that of FC.
View details for DOI 10.14309/ajg.0000000000002518
View details for PubMedID 37753938
-
The Serum-Based Endoscopic Healing Index Can Monitor Therapeutic Response in Crohn's Disease.
Journal of Crohn's & colitis
2023; 17 (10): 1703-1704
View details for DOI 10.1093/ecco-jcc/jjad077
View details for PubMedID 37178692
-
Evaluation of serum cytokines and acute phase proteins as possible pharmacodynamic biomarkers to monitor endoscopic remission during ustekinumab therapy in patients with Crohn's disease.
Therapeutic advances in gastroenterology
2023; 16: 17562848231189110
Abstract
Since not all Crohn's disease (CD) patients respond adequately to ustekinumab therapy, biomarkers could aid to monitor treatment response and optimize therapeutic outcomes.To explore the dynamics of serum biomarker concentrations to monitor the response to ustekinumab treatment in CD patients.Retrospective, exploratory study to evaluate concentrations of serum cytokines and acute phase proteins and their relation to endoscopic remission in CD patients during ustekinumab treatment.Serum concentrations of 16 proteins including cytokines and acute phase proteins were measured using the Mesoscale Discovery Platform in serum of healthy controls (n = 13), and CD patients (n = 61) at baseline (week 0), week 8 and week 24 during ustekinumab treatment. Endoscopic remission was defined as simple endoscopic score for CD (SES-CD) <3 after 6 months of therapy.Absolute concentrations of serum amyloid A protein (SAA; week 8), IL-6 (week 24), AGP (weeks 8 and 24), interferon (IFN)-γ (weeks 8 and 24), lipopolysaccharide binding protein (LBP; weeks 8 and 24) and IL-22 (weeks 8 and 24) were significantly lower in endoscopic remitters compared to non-responders (p-values ranging between <0.001 and <0.05). SAA (week 8) and AGP (week 24) were the biomarkers with the highest area under the ROC curve (AUROC; 0.761 and 0.760, respectively) for identifying patients in endoscopic remission, though their performance was not superior to C-reactive protein (CRP) or faecal calprotectin. AUROCs of the predictive probability of biomarker combinations showed superiority in discriminating endoscopic remitters from non-responders in comparison to single biomarker measurements, but not as compared to faecal calprotectin.Although not superior to faecal calprotectin, measurement of AGP, SAA, LBF, IFN-γ, IL-6 and IL-22 concentrations, and combinations thereof with or without CRP and faecal calprotectin, during ustekinumab therapy might contribute to adequate monitoring of treatment response in CD patients.
View details for DOI 10.1177/17562848231189110
View details for PubMedID 37655059
View details for PubMedCentralID PMC10467236
-
Comparative Effectiveness Research to Position Therapies in Ulcerative Colitis: How Fair Are the Comparisons?
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
2023; 21 (5): 1372-1373
View details for DOI 10.1016/j.cgh.2022.06.017
View details for PubMedID 35850410
-
Real-world Endoscopic and Histological Outcomes Are Correlated with Ustekinumab Exposure in Patients with Ulcerative Colitis.
Journal of Crohn's & colitis
2022; 16 (10): 1562-1570
Abstract
Histo-endoscopic outcomes are being proposed as new treatment targets in ulcerative colitis [UC]. Little is known about the pharmacokinetic-pharmacodynnamic [PK-PD] relationship of ustekinumab [UST] in UC patients or whether serum UST concentrations reflect tissue drug exposure. We aimed to study UST serum concentrations and their relation to tissue exposure and drug effectiveness in a real-world setting.A total of 42 UC patients starting UST were prospectively followed by clinical, endoscopic and histological assessments at Week 16. Histological remission was defined as Nancy Histology Index of 0. Analogous to the UNIFI programme, histo-endoscopic mucosal improvement was defined as a combination of histological improvement [Geboes ≤3.1] and endoscopic improvement [MES ≤1]. Paired trough serum samples and colonic mucosal biopsies were collected for UST levels measurement.After 16 weeks [IQR 15.8-16.4] of therapy, histological remission and histo-endoscopic mucosal improvement were observed in 19 [45%] and 18 [43%] patients, respectively. Patients who achieved these outcomes had higher serum UST levels than those who did not. Patients with shorter disease duration and clinical response at Week 8 had higher odds to achieve histological remission. UST concentrations from paired serum and biopsy samples revealed a strong positive correlation [r = 0.88, p < 0.001], in both inflamed and uninflamed tissue.In this real-world cohort of refractory UC patients initiating UST, more than a third of the patients achieved histological remission. A drug exposure-response relationship was observed for histo-endoscopic outcomes, with no added value of measuring tissue exposure given the strong correlation with serum exposure.
View details for DOI 10.1093/ecco-jcc/jjac067
View details for PubMedID 35533353
-
Adalimumab versus ustekinumab as first-line biological in moderate-to-severe Crohn's disease: real-life cohort from a tertiary referral center.
European journal of gastroenterology & hepatology
2022; 34 (10): 1015-1020
Abstract
Therapeutic options for Crohn's disease are growing, making the choice of first-line therapy relevant. Both adalimumab and ustekinumab are effective in moderate-to-severe Crohn's disease. The Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year trial suggested no difference in clinical or endoscopic remission at week 52 in biological-naive Crohn's disease patients. We explored if results withstand in the real world.We included bio-naive Crohn's disease patients starting adalimumab or ustekinumab between 2017 and 2020. Patients had endoscopy-proven moderate-to-severe disease [Simple Endoscopic Score for Crohn's disease (SES-CD) ≥3]. Clinical remission was defined as Harvey Bradshaw Index (HBI) <5 or physician global assessment. Endoscopic remission (SES-CD <3) and improvement (≥50% reduction in SES-CD from baseline) were assessed at W26-52. Propensity score matching was used.A total of 68 biological-naive Crohn's disease patients were included (32 adalimumab and 32 ustekinumab) and followed for median of (IQR) 60 (33-104) weeks. Patients had significantly higher odds of achieving endoscopic remission with adalimumab than ustekinumab [adjusted odds ratio (aOR), 2.73; confidence interval (CI), 1.12-7.36; P = 0.03]. Also, more adalimumab-treated patients achieved endoscopic response, clinical remission at week 26 and 52 (aOR, 2.24; CI, 0.94-5.71; P = 0.07; aOR, 1.26; CI, 0.36-4.51; P = 0.72; aOR, 1.58; CI, 0.54-4.88; P = 0.41, respectively). Treatment persistence was not different between groups (P = 0.44). The number of adverse events was similar.In a real-world cohort of biological-naive Crohn's disease patients, adalimumab was superior to ustekinumab in achieving endoscopic remission. No differences in clinical remission at W26-52 or treatment persistence were observed. Both adalimumab and ustekinumab remain good options as first-line biologicals in moderate-to-severe Crohn's disease.
View details for DOI 10.1097/MEG.0000000000002411
View details for PubMedID 36062494
-
Tailoring Multi-omics to Inflammatory Bowel Diseases: All for One and One for All.
Journal of Crohn's & colitis
2022; 16 (8): 1306-1320
Abstract
Inflammatory bowel disease [IBD] has a multifactorial origin and originates from a complex interplay of environmental factors with the innate immune system at the intestinal epithelial interface in a genetically susceptible individual. All these factors make its aetiology intricate and largely unknown. Multi-omic datasets obtained from IBD patients are required to gain further insights into IBD biology. We here review the landscape of multi-omic data availability in IBD and identify barriers and gaps for future research. We also outline the various technical and non-technical factors that influence the utility and interpretability of multi-omic datasets and thereby the study design of any research project generating such datasets. Coordinated generation of multi-omic datasets and their systemic integration with clinical phenotypes and environmental exposures will not only enhance understanding of the fundamental mechanisms of IBD but also improve therapeutic strategies. Finally, we provide recommendations to enable and facilitate generation of multi-omic datasets.
View details for DOI 10.1093/ecco-jcc/jjac027
View details for PubMedID 35150242
View details for PubMedCentralID PMC9426669
-
Translating Results from VARSITY to Real World: Adalimumab vs Vedolizumab as First-line Biological in Moderate to Severe IBD.
Inflammatory bowel diseases
2022; 28 (8): 1135-1142
Abstract
Selecting a first-line therapy remains challenging in IBD. Adalimumab (ADM) and vedolizumab (VDZ) effectively lead to endoscopic remission in moderate to severe IBD. The VARSITY trial showed superiority of VDZ over ADM in ulcerative colitis (UC) regarding clinical remission and endoscopic improvement at week 52. We explored these results in a real-world setting of UC and Crohn's disease (CD).This retrospective study followed a cohort of biologic-naïve patients starting ADM or VDZ from 2015-2019. Patients had moderate to severe disease (endoscopic Mayo score ≥2 for UC, presence of ulcerations for CD) prior to therapy initiation. For UC, endoscopic remission (endoscopic Mayo score 0) and improvement (endoscopic Mayo score ≤1) at week 52 were assessed. For CD, endoscopic remission (absence of ulcerations) and improvement (markedly better endoscopy despite ulcerations) at weeks 26-52 were studied. Treatment persistence was also evaluated.In total, 195 biologic-naïve patients (109 UC; 86 CD) were included. In UC, VDZ was superior to ADM regarding endoscopic remission (29% vs 11%, P = .03), endoscopic improvement (51% vs 26%, P = .01) at week 52, and treatment persistence (P = .04). In CD, no differences in endoscopic remission (VDZ 48% vs ADM 60%; P=0.37), improvement (VDZ 76% vs ADM 77%; P = 1.00), or treatment persistence (P=0.43) at weeks 26-52 were seen. Safety profiles were similar in UC and CD.This real-world cohort study of biologic-naïve IBD patients found VDZ to be superior to ADM as first-line treatment for patients with UC-but not CD-regarding endoscopic remission at week 52 and treatment persistence.
View details for DOI 10.1093/ibd/izab257
View details for PubMedID 34751766
-
Longitudinal monitoring of STAT3 phosphorylation and histologic outcome of tofacitinib therapy in patients with ulcerative colitis.
Alimentary pharmacology & therapeutics
2022; 56 (2): 282-291
Abstract
Tofacitinib is the first in class, pan-JAK inhibitor approved for ulcerative colitis (UC). Clinical efficacy has been shown, but long-term real-life endoscopic and histologic data are lacking.To investigate the effects of tofacitinib in patients with refractory UC focussing on endoscopic, histologic and molecular outcomes, including STAT3 phosphorylation (pSTAT3) detection in the spatial context of mucosal inflammation METHODS: We prospectively monitored 59 highly refractory patients (96.7% anti-TNF exposure, 91.7% vedolizumab exposure) initiating tofacitinib at two IBD referral centres and assessed outcome at the end of induction and after 48 weeks of therapy. Endoscopic improvement was defined as a Mayo endoscopic subscore ≤1, endoscopic and histologic remission as Mayo endoscopic subscore 0 and Nancy histologic score 0. Multiplex immunohistochemistry with multispectral imaging was used to assess pSTAT3.Endoscopic improvement was achieved by 24.4% and 30.5% of patients at weeks 8 and 48, respectively. Endoscopic and histologic remission rates were 11.1%, 23.7 and 16.7%, 21.4%, respectively. Endoscopic improvement at week 8 was significantly associated with treatment continuation in the long-term (72.7% vs 20.6%, p = 0.003). Although we observed a gradual decrease of mucosal pSTAT3 levels in both remitters and non-remitters (p < 0.05), no association with treatment outcome could be demonstrated. However, lamina propria pSTAT3 was significantly associated with the Nancy Histologic index (p = 0.004).Tofacitinib can induce and maintain endoscopic and histologic remission in up to one-quarter of highly refractory UC patients. Longitudinal monitoring of nuclear pSTAT3 in mucosal tissue compartments reflects distinctive on-target effects, independently of long-term treatment outcomes.
View details for DOI 10.1111/apt.16955
View details for PubMedID 35484689
-
Letter: immunogenicity is not the root cause for loss of response to anti-TNF agents in patients with IBD in TDM era.
Alimentary pharmacology & therapeutics
2022; 55 (7): 885-886
View details for DOI 10.1111/apt.16797
View details for PubMedID 35315101
-
Biomarker discovery for personalized therapy selection in inflammatory bowel diseases: Challenges and promises.
Current research in pharmacology and drug discovery
2022; 3: 100089
Abstract
The past decades witnessed a significant stride in deciphering the pathophysiology of inflammatory bowel disease, which further advanced drug development adding several new biologicals and small molecules to the arsenal of available therapies. Surprisingly, this wealth in therapeutic options did not yield the aspired high durable response rates. In addition, the increase in therapeutic availabilities ignited an increase in research toward biomarkers that could help assign therapies to patients with the highest probability of response. Luckily, major steps have been undertaken in this domain which resulted in the discovery of some interesting biomarkers that are still under validation. However, the pace in which this domain is progressing, the discordance between short-term endpoints in biomarker discovery studies and the ambition of the disease community in modifying disease course, and the uncertainties about the validity of discovered biomarkers highlight the need for a critical appraisal of research conduct in this domain. In this review, we shed light on areas of improvement in biomarker discovery studies that will help optimize the use of available therapies and break the current therapeutic ceiling.
View details for DOI 10.1016/j.crphar.2022.100089
View details for PubMedID 35146421
View details for PubMedCentralID PMC8818904
-
The effect of aging on infliximab exposure and response in patients with inflammatory bowel diseases.
British journal of clinical pharmacology
2021; 87 (10): 3776-3789
Abstract
Controversies regarding infliximab treatment in elderly patients with inflammatory bowel diseases remain. We evaluated the effect of patient's age on infliximab exposure, efficacy and safety.Retrospective case-control data of patients receiving infliximab induction treatment were analysed. A population pharmacokinetic model was developed to estimate individual pharmacokinetic parameters. A logistic regression model was used to investigate the effect of exposure on endoscopic remission. Repeated time-to-event models were developed to describe the hazard of safety events over time.A total of 104 patients (46 elderly, ≥65 years) were included. A two-compartment population pharmacokinetic model with linear elimination adequately described the data. Infliximab clearance decreased with older age, higher serum albumin, lower fat-free mass, lower C-reactive protein and absence of immunogenicity. Yet, infliximab exposure was not significantly different between elderly and nonelderly. Regardless of age, an infliximab trough concentration at week (w)14 of 15.6 mg/L was associated with a 50% probability of attaining endoscopic remission between w6 and w22. Infliximab exposure during induction treatment was not a risk factor of (severe) adverse events. The hazard of severe adverse events and malignancy increased by 2% and 7%, respectively, with increasing year of age. Concomitant immunomodulator use increased the hazard of infection by 958%, regardless of age.Elderly patients attained infliximab exposure and endoscopic remission similarly to nonelderly patients. Therefore, the same infliximab trough concentration target can be used in therapeutic drug monitoring. The hazards of severe adverse events and malignancy increased with age, but not with infliximab exposure.
View details for DOI 10.1111/bcp.14785
View details for PubMedID 33604964
-
Breaking the therapeutic ceiling in drug development in ulcerative colitis.
The lancet. Gastroenterology & hepatology
2021; 6 (7): 589-595
Abstract
Increased knowledge of the intricate pathogenesis of ulcerative colitis has triggered an advance in drug development during the past two decades, resulting in the advent of several biological agents and small-molecule therapies. Although the increase in therapeutic options is positive, remission rates of patients with ulcerative colitis given new therapeutic agents in induction trials remain at a modest 20-30%, seemingly facing a so-called therapeutic ceiling. This therapeutic ceiling requires a critical appraisal and highlights the need for alternative strategies for drug development. In this Review, we objectively itemise the boundaries of therapeutic efficacy in ulcerative colitis, provide possible explanations for the shortcomings of current strategies, and propose solutions to achieve better therapeutic outcomes in ulcerative colitis.
View details for DOI 10.1016/S2468-1253(21)00065-0
View details for PubMedID 34019798
-
Monitoring vedolizumab and ustekinumab drug levels in patients with inflammatory bowel disease: hype or hope?
Current opinion in pharmacology
2020; 55: 17-30
Abstract
Therapeutic drug monitoring (TDM) plays a vital role in implementing precision medicine in inflammatory bowel disease (IBD), and may contribute to increased effectiveness, lower rates of drug toxicity and cost savings. While expert panels advocate the use of reactive TDM for anti-tumor necrosis factor (anti-TNF) agents, TDM is not yet widely recommended for non-anti TNF biologicals. We provide an overview of the observational evidence of the value of TDM in case of vedolizumab and ustekinumab. We also shed light on obstacles that need to be addressed before establishing wide acceptance of TDM in the field of IBD. In this respect, new analytical techniques and modelling approaches are being developed to further optimize efficacy of TDM and to facilitate general acceptance of this tool in personalizing IBD management.
View details for DOI 10.1016/j.coph.2020.09.002
View details for PubMedID 33039940
https://orcid.org/0000-0002-6795-6328